Date: 2017-01-05
Type of information: Nomination
Compound: chief executive officer
Company: Therachon (Switzerland)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 5, 2017, Therachon announced it has appointed Luca Santarelli as chief executive officer and director. Dr. Santarelli brings over 20 years of experience in academic, industrial research and development, and business experience from his role as Venture Partner at Versant Ventures. In addition to his training as both a discovery scientist and clinician, Dr. Santarelli has deep operating experience from his progressive leadership responsibilities at Roche, most recently serving as senior vice president and global head of neuroscience, ophthalmology and rare diseases. In this capacity, he built a multi-disciplinary team and led efforts spanning from drug discovery to early development. Luca also provided strategic and operational leadership for many of the Roche external biotech collaborations and helped instill a more entrepreneurial culture in the broader R&D organization. Luca received his medical and scientific training at the University of Turin (Italy) and post-doctorate training at Columbia University (USA), where he also co-founded a venture-backed start-up while on faculty.
Financial terms:
Latest news:
Is general: Yes
